Related Experiment Videos
Identification of dilated cardiomyopathy signature genes through gene expression and network data integration
Anyela Camargo1, Francisco Azuaje
1School of Computing and Mathematics, University of Ulster at Jordanstown, Shore Road, Newtownabbey, County Antrim BT37 0QB, Northern Ireland, UK.
Insights
This study identifies reliable dilated cardiomyopathy (DCM) signature genes by integrating multiple datasets. These findings improve biomarker discovery for heart failure and cardiac transplantation.
Area of Science:
- Cardiovascular Research
- Genomics
- Biomarker Discovery
Background:
- Dilated cardiomyopathy (DCM) is a primary cause of heart failure and cardiac transplantation.
- Previous gene expression studies lacked robustness due to diverse experimental settings.
- Reproducibility of potential biomarkers and drug targets remains a concern.
Purpose of the Study:
- To identify robust and reproducible DCM signature genes.
- To develop reliable clinical diagnostic models for DCM.
- To demonstrate the superiority of integrative analysis over single-source approaches.
Main Methods:
- Integration of gene expression profiles from three independent public datasets (DCM vs. non-DCM).
- Analysis of differentially expressed genes within a global protein-protein interaction network.
- Development and evaluation of integrative classification models for DCM diagnosis.
Main Results:
- Identification of a set of integrated, potentially novel DCM signature genes.
- Demonstration of robust and reproducible gene signatures through data integration.
- Validation of integrative classification models for differentiating DCM from non-DCM samples.
Conclusions:
- The identified DCM signature genes serve as reliable biomarkers for disease diagnosis.
- Integrative analysis enhances the robustness and reproducibility of gene expression findings.
- This approach offers a powerful tool for advancing DCM research and clinical applications.
Abstract:
Dilated cardiomyopathy (DCM) is a leading cause of heart failure (HF) and cardiac transplantations in Western countries. Single-source gene expression analysis studies have identified potential disease biomarkers and drug targets. However, because of the diversity of experimental settings and relative lack of data, concerns have been raised about the robustness and reproducibility of the predictions. This study presents the identification of robust and reproducible DCM signature genes based on the integration of several independent data sets and functional network information. Gene expression profiles from three public data sets containing DCM and non-DCM samples were integrated and analyzed, which allowed the implementation of clinical diagnostic models. Differentially expressed genes were evaluated in the context of a global protein-protein interaction network, constructed as part of this study. Potential associations with HF were identified by searching the scientific literature. From these analyses, classification models were built and their effectiveness in differentiating between DCM and non-DCM samples was estimated. The main outcome was a set of integrated, potentially novel DCM signature genes, which may be used as reliable disease biomarkers. An empirical demonstration of the power of the integrative classification models against single-source models is also given.